Americans Want FDA to End Peptide Roulette, New National Poll Finds

The FDA’s peptide vote could create telehealth's next multibillion-dollar market | Fortune

As regulators weigh whether pharmacies can legally compound wellness peptides, companies are preparing for a repeat of the GLP-1 boom—only this time with even murkier science.